Overview

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Status:
Completed
Trial end date:
2020-01-27
Target enrollment:
Participant gender:
Summary
This study will examine the pharmacokinetics (PK) of omaveloxolone following a single oral dose of omaveloxolone in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.